Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain JNJ message board posts where the ticker symbol JNJ has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest JNJ SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 2.02, 8.01, and 9.01
Acc-no: 0000200406-18-000049 (34 Act)  Size: 2 MB
2018-10-16 001-03215
181123550
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0000200406-18-000046 (34 Act)  Size: 37 KB
2018-10-02 001-03215
181102158
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-013499 Size: 5 KB
2018-09-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-013377 Size: 4 KB
2018-09-13
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-013376 Size: 5 KB
2018-09-13
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-013320 Size: 6 KB
2018-09-11
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-012945 Size: 9 KB
2018-08-28
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000200406-18-000041 (34 Act)  Size: 18 MB
2018-08-02 001-03215
18986275
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000904454-18-000479 (34 Act)  Size: 9 KB
2018-07-20 001-38552
18961674
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0000200406-18-000039 (34 Act)  Size: 2 MB
2018-07-17 001-03215
18955491
More JNJ SEC Filings


Related news from
Fri, 19 Oct 2018
19:50:02 +0000
An Overview of JNJ’s Women’s Health & Wound Care Businesses
Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.
Fri, 19 Oct 2018
18:20:02 +0000
A Performance Overview of JNJ’s Beauty and OTC Businesses
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
Fri, 19 Oct 2018
17:51:00 +0000
What's Behind Johnson & Johnson's Q3 Earnings Success
Here's why this healthcare giant is out-performing analyst expectations.
Fri, 19 Oct 2018
14:31:44 +0000
What’s Pfizer’s Current Valuation?
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
Fri, 19 Oct 2018
13:02:04 +0000
Pfizer’s Dividends and Earnings Quality
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
Fri, 19 Oct 2018
12:36:02 +0000
10 S&P 500 Stocks to Buy for the Long Term
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance
Fri, 19 Oct 2018
11:33:18 +0000
Pfizer Reported Revenue Growth in Global Markets
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
Fri, 19 Oct 2018
01:21:00 +0000
Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
Fri, 19 Oct 2018
00:42:03 +0000
Intuitive Surgical Earnings miss, Revenue beats In Q3
Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.
Thu, 18 Oct 2018
20:05:02 +0000
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Thu, 18 Oct 2018
19:08:07 +0000
Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
Thu, 18 Oct 2018
17:53:16 +0000
Novartis Missed Revenue Estimates in Q3 2018
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
Thu, 18 Oct 2018
17:03:16 +0000
Pfizer’s Market Cap and Shareholding Pattern
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
Thu, 18 Oct 2018
17:03:10 +0000
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
Thu, 18 Oct 2018
12:05:00 +0000
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018
NEW BRUNSWICK, N.J., Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock.  The dividend is payable on December 11, 2018 to shareholders of record at the close of business on November 27, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
Wed, 17 Oct 2018
21:03:00 +0000
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
Wed, 17 Oct 2018
20:42:45 +0000
They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more
After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.
Wed, 17 Oct 2018
19:42:24 +0000
Edited Transcript of JNJ earnings conference call or presentation 16-Oct-18 12:30pm GMT
Q3 2018 Johnson & Johnson Earnings Call
Wed, 17 Oct 2018
14:54:03 +0000
Abbott Labs Earnings, Revenue beat in Q3
Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.
Wed, 17 Oct 2018
14:47:58 +0000
STOCKS on the move: Netflix, Facebook, McDonald's, J&J, Home Depot, IBM
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is a great group of value seeking investors, who are most generous in sharing their research, news, business expertise, and investment experience. It is an invaluable resource, and brings many 'lessons learned' to the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards